<DOC>
	<DOCNO>NCT00747487</DOCNO>
	<brief_summary>This study mean assess effectiveness idebenone visual function measure patient Leber 's Hereditary Optic Neuropathy 6 month period .</brief_summary>
	<brief_title>Study Assess Efficacy , Safety Tolerability Idebenone Treatment Leber 's Hereditary Optic Neuropathy</brief_title>
	<detailed_description>The study involve 6 clinic visit .</detailed_description>
	<mesh_term>Peripheral Nervous System Diseases</mesh_term>
	<mesh_term>Optic Nerve Diseases</mesh_term>
	<mesh_term>Optic Atrophy , Hereditary , Leber</mesh_term>
	<mesh_term>Idebenone</mesh_term>
	<mesh_term>Ubiquinone</mesh_term>
	<criteria>Age &gt; = 14 year &lt; 65 year Impaired visual acuity least one eye due LHON Onset visual loss due LHON lie five year less prior Baseline Confirmation either G11778A , T14484C G3460A LHON mtDNA mutation &gt; 60 % blood No explanation visual failure besides LHON Body weight â‰¥ 45 kg Negative urine pregnancy test Screening Baseline ( woman childbearing potential ) . Treatment Coenzyme Q10 idebenone within 1 month prior Baseline Pregnancy and/or breastfeed Weekly alcohol intake 35 unit ( men ) 24 unit ( woman ) Current drug abuse Clinically significant abnormality clinical haematology biochemistry include , limited , elevation great 2 time upper limit normal AST , ALT creatinine Participation another clinical trial investigational drug within 3 month prior Baseline Other factor , investigator 's opinion , excludes patient enter study</criteria>
	<gender>All</gender>
	<minimum_age>14 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>May 2013</verification_date>
	<keyword>Leber</keyword>
	<keyword>LHON</keyword>
	<keyword>Leber 's Hereditary Optic Neuropathy</keyword>
	<keyword>Idebenone</keyword>
</DOC>